2021年5月20日(木) 08:00 〜 09:30 第4会場 (国立京都国際会館 2F Room A)

座長：五十嵐 久佳(富士通クリニック内科（頭痛外来）),髙橋 牧郎(日本赤十字社 大阪赤十字病院 脳神経内科)

後援：日本頭痛学会

Migraine is a common disabling primary headache disorder that is highly prevalent and imposes a significant burden on patients, society, and the healthcare system, in many parts of the world. The anti-CGRP receptor monoclonal antibody (erenumab) and anti-CGRP monoclonal antibodies such as fremanezumab, galcanezumab and epitinezumab are newer drugs approved by the FDA in 2018 for prophylactic treatment of migraine.
The 5-HT1F receptor agonist (Lasmiditan) and oral calcitonin gene-related peptide (CGRP) receptor antagonists (ubrogepant) are also approved for acute treatment of migraine by the FDA. Some of these new drugs will be available in Japan in 2021. Neurologists should know how the emergence of these drugs has changed migraine management in the real world and it is important to know whether patients are satisfied with those treatments.